USE OF alpha-2,6-SIALYLATED IMMUNOGLOBULIN IN PREVENTING OR TREATING DRY EYE SYNDROME OR INFLAMMATORY EYE DISEASES
AssigneeKonkuk University Industrial Cooperation Corp.
InventorsYoung-Sun KANG, Joon Young KIM, Hyeongjwa CHOI, Ha-Eun LEE
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of α-2,6-sialylated immunoglobulin derived from human blood in prevent or treating dry eye syndrome or inflammatory eye diseases. The α-2,6-sialylated immunoglobulin according to the present invention, compared to IVIG, exhibits excellent therapeutic effects for dry eye syndrome even at a low dose without side effects such as fibrosis of corneal tissue, and also for intractable inflammatory eye diseases of varying severity.
Claims14
A method for preventing or treating dry eye syndrome or inflammatory eye disease, the method comprising administering a pharmaceutical composition comprising sialylated immunoglobulin to a subject in need thereof.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.